Lundbeck CEO Charl van Zyl describes the rationale for today's $2.6 billion acquisition of Longboard Pharma
He explains the market opportunity he sees for Bexicaserin and the data that made him comfortable to pull the trigger on the deal today ahead of a phase 3 study.